Neural Regeneration Research (Jan 2018)

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models

  • Lan-Xiang Liu,
  • Dan Du,
  • Zhan-Qiu Wang,
  • Yuan Fang,
  • Tao Zheng,
  • Yan-Chao Dong,
  • Qing-Lei Shi,
  • Min Zhao,
  • Fang Xiao,
  • Juan Du

DOI
https://doi.org/10.4103/1673-5374.235076
Journal volume & issue
Vol. 13, no. 7
pp. 1276 – 1280

Abstract

Read online

Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson’s disease were generated by injection of 3 μg rotenone or 10 μg 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2* values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2* values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson’s disease over long periods.

Keywords